Presenter beware
Executive Summary
FDA is freezing clinical development of an investigational cancer drug based on trial results presented at the American Society of Clinical Oncology June 3. Under the clinical hold, Telik stops treatment with Telcyta (canfosfamide) in trials after two studies in second-line advanced platinum refractory or resistant ovarian cancer and one study in third-line NSCLC failed to show benefit with treatment...